Revenue
2019
2020
2021
2022
2023
2024
2025
4D Molecular Therapeutics, Inc. (FDMT)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $85.2M | $37,000 | $20.7M | $3.1M | $18.0M | $13.4M | $7.0M |
| Research & development | $195.7M | $141.3M | $97.1M | $80.3M | $61.4M | $53.0M | $38.7M |
| Operating expenses | $244.8M | $187.9M | $133.6M | $113.2M | $89.4M | $70.3M | $57.8M |
| Operating income | −$159.5M | −$187.8M | −$112.9M | −$110.0M | −$71.3M | −$56.7M | −$50.8M |
| EBITDAderived | −$154.9M | −$183.2M | −$108.7M | −$107.6M | −$69.8M | −$55.2M | −$49.8M |
| Net income | −$140.1M | −$160.9M | −$100.8M | −$107.5M | −$71.3M | −$56.7M | −$49.3M |
| Basic EPSper diluted share | -$2.42 | -$2.98 | -$2.58 | -$3.32 | -$2.57 | -$8.82 | -$9.59 |
| Diluted EPSper diluted share | -$2.42 | -$2.98 | -$2.58 | -$3.32 | -$2.57 | -$8.82 | -$9.59 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 23, 2026Form 4 · 10b5-1 | Bizily ScottChief Legal Officer | SellCommon Stock | 9.8K | $12.00 | $117.7K | 8.6K |
| Jun 22, 2026Form 4 · 10b5-1 | Kirn DavidSee Remarks | SellCommon Stock | 114.7K | $10.47 | $1.20M | 942.5K |
| Jun 1, 2026Form 4 · 10b5-1 | Kirn DavidSee Remarks | SellCommon Stock | 1.9K | $10.02 | $19.3K | 1.06M |
| Mar 20, 2026Form 4 | Gupta AshooVP, Finance and Controller | SellCommon Stock | 80 | $8.61 | $688.80 | 47.1K |
| Mar 20, 2026Form 4 | Gupta AshooVP, Finance and Controller | SellCommon Stock | 310 | $8.61 | $2.7K | 46.9K |